IL2 and neoplasm: Strategies such as immune checkpoint inhibitors (e.g., PD-1/PD-L1 and CTLA-4 inhibitors), cytokine-based therapies (e.g., IL-2), tumor vaccines, and chimeric antigen receptor T (CAR-T) cells represent major advancements in this field and are increasingly being used in the treatment of various cancers [10,11,12].